Edging Into the Mainstream
Low dose naltrexone (LDN) is slowly edging into the mainstream. Strong patient reports plus some small studies have made LDN a hot item in many disease communities. A book is about to be published and a standardized compound is being produced for studies. The field is slowly but surely moving forward.
[fright]
[/fright]
Recently, the SMCI's Biovista drug repurposing project gave a LDN another boost. It's massing data mining analysis of thousands of drugs gave low dose naltrexone drug combination the top score (out of thousands of drugs) in potential efficacy for chronic fatigue syndrome (ME/CFS). (Could we see an NIH sponsored LDN ME/CFS trial?)
(Please note a mistake in the last blog; the Solve ME/CFS Initiative did not, as a Wall St. Journal article reported - and I repeated - spend $250,000 on the Biovista project; it spent much less.)
LDN's not mainstream yet but it's getting closer and this year's LDN Research Trust Conference in Orlando, Florida shows that. The success of a conference depends on its speakers and the speakers are getting better.
Talks
The top of my list of this three day conference would be:
THE LDN Book is also being launched at the conference. It will provide a "comprehensive resource for doctors, pharmacists, and patients".
Viewing the Conference
The conference runs from Feb 19th - 21st in Orlando, Fl. If you can't attend you can view a live-stream of the conference for $55. Find out how to do that here.
Besides the information you can get at the conference attending simply supports a good cause. LDN, like ME/CFS and FM, is working to breakthrough into the mainstream. The sooner it does that the better. The LDN Research Trust is at the forefront of making that happen.
Low dose naltrexone (LDN) is slowly edging into the mainstream. Strong patient reports plus some small studies have made LDN a hot item in many disease communities. A book is about to be published and a standardized compound is being produced for studies. The field is slowly but surely moving forward.
[fright]
[/fright]
Recently, the SMCI's Biovista drug repurposing project gave a LDN another boost. It's massing data mining analysis of thousands of drugs gave low dose naltrexone drug combination the top score (out of thousands of drugs) in potential efficacy for chronic fatigue syndrome (ME/CFS). (Could we see an NIH sponsored LDN ME/CFS trial?)
(Please note a mistake in the last blog; the Solve ME/CFS Initiative did not, as a Wall St. Journal article reported - and I repeated - spend $250,000 on the Biovista project; it spent much less.)
LDN's not mainstream yet but it's getting closer and this year's LDN Research Trust Conference in Orlando, Florida shows that. The success of a conference depends on its speakers and the speakers are getting better.
Talks
The top of my list of this three day conference would be:
- Jarred Younger's talk on day two not on LDN and fibromyalgia or ME/CFS but on "Calming microglia: a future method for treating multiple sclerosis." Calming the microglia is something of obvious interest in ME./CFS but Younger, a very insightful guy, apparently has some insights on LDN's effects on MS he wants to impart.
- Right on the heels of Younger's talk is a not to be missed. Skip Lenz, pharmacologist and founder of Skip's Pharmacy is something of a legend in LDN circles for his ability to compound LDN effectively. He'll be reporting on the results of a study of LDN's effects.
- A couple of hours later Dr. Holtorf, an authority on hypothyroidism will speak on ME/CFS treatments. I found his talk in the last Conference really intriguing. Among his many interesting points, Holtorf said he found a blood thinning drug to be really helpful at times. That's not an approach you'll get from many other doctors.
- Dr. Padrep Chopra's talk on using LDN for chronic pain has obvious appeal
- Dr. Shulman's report that he finds LDN helpful in the treatment of sexual dysfunction should perk up a few er...ears. Shulman is a psychiatrist who combines medications with vitamins, supplements and reflexotherapy.
- Dr. Armin Schwarzbach, a German doctor, will give his thoughts on a subject many are concerned with - Lyme disease and how to effectively test for it.
- Stephen Dickson's talk on how LDN is absorbed and metabolized will provide some cautions with the drug for those using it.
- Feeling anxious, hypervigilant or having sleep issues since you came down with ME/CFS/FM? (Yes, to all three for me ). Galyn Forster, MS will talk how using LDN can reduce anxiety, hypervigilance and help with sleep.
THE LDN Book is also being launched at the conference. It will provide a "comprehensive resource for doctors, pharmacists, and patients".
Viewing the Conference
The conference runs from Feb 19th - 21st in Orlando, Fl. If you can't attend you can view a live-stream of the conference for $55. Find out how to do that here.
Besides the information you can get at the conference attending simply supports a good cause. LDN, like ME/CFS and FM, is working to breakthrough into the mainstream. The sooner it does that the better. The LDN Research Trust is at the forefront of making that happen.
Health Rising does not receive any funds from live-stream or other sales.
Last edited: